| Drug Name |
Reteplase |
| Drug ID |
BADD_D01929 |
| Description |
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). |
| Indications and Usage |
For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction |
| Marketing Status |
Prescription |
| ATC Code |
B01AD07 |
| DrugBank ID |
DB00015
|
| KEGG ID |
D05721
|
| MeSH ID |
C087896
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0T1UJ
|
| NDC Product Code |
10122-141; 72820-100; 10122-143 |
| Synonyms |
reteplase | 173-527-plasminogen activator (human tissue-type), 173-L-serine-174-L-tyrosine-175-L-glutamine- | BM 06.022 | BM 06022 | BM-06.022 | Rapilysin | Retavase |
